Who are Estrace® Vaginal Cream USP, 0.01%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Estradiol Vaginal Cream, 0.01%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/estrace-vaginal-cream-usp-0-01.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Estrace® Vaginal Cream USP, 0.01% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Estrace® Vaginal Cream USP, 0.01% (Estrace® Vaginal Cream USP, 0.01%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen replacement therapy (local/vaginal). Area: Gynecology / Menopause.

phase 3 Estrogen replacement therapy (local/vaginal) Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Gynecology / Menopause Small molecule Live · refreshed every 30 min

Target snapshot

Estrace® Vaginal Cream USP, 0.01% (Estrace® Vaginal Cream USP, 0.01%) — Actavis Inc.. Estrace vaginal cream delivers estradiol directly to vaginal tissue to restore estrogen levels and relieve symptoms of vaginal atrophy and urogenital aging.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estrace® Vaginal Cream USP, 0.01% TARGET	Estrace® Vaginal Cream USP, 0.01%	Actavis Inc.	phase 3	Estrogen replacement therapy (local/vaginal)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estradiol Vaginal Cream, 0.01%	Estradiol Vaginal Cream, 0.01%	Mylan Pharmaceuticals Inc	phase 3	Estrogen replacement therapy (local/vaginal)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen replacement therapy (local/vaginal) class)

Actavis Inc. · 1 drug in this class
Mylan Pharmaceuticals Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estrace® Vaginal Cream USP, 0.01% — Competitive Intelligence Brief. https://druglandscape.com/ci/estrace-vaginal-cream-usp-0-01. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab